PT - JOURNAL ARTICLE AU - NURHANAN M. YUNOS AU - SITI S.M. MUTALIP AU - MUHAMMAD H. JAURI AU - JUN Q. YU AU - FAZLUL HUQ TI - Anti-proliferative and Pro-apoptotic Effects from Sequenced Combinations of Andrographolide and Cisplatin on Ovarian Cancer Cell Lines DP - 2013 Oct 01 TA - Anticancer Research PG - 4365--4371 VI - 33 IP - 10 4099 - http://ar.iiarjournals.org/content/33/10/4365.short 4100 - http://ar.iiarjournals.org/content/33/10/4365.full SO - Anticancer Res2013 Oct 01; 33 AB - Andrographolide (Andro) is a diterpenoid that is isolated from Andrographis paniculata and reported to be active against several cancer cell lines. However, few in-depth studies have been carried out on its effects on ovarian cancer cell lines alone or in combination with cisplatin (Cis), which is commonly used to treat ovarian cancer. The aim of this study was to determine the anti-proliferative and apoptotic effects of Andro administered alone and in combination with Cis in the ovarian A2780 and A2780cisR cancer cell lines using five different sequences of administration (Cis/Andro h): 0/0h, 4/0 h, 0/4 h, 24/0 h and 0/24 h. The results were evaluated in terms of medium-effect dose (Dm) and combination indices (CI) using the CalcuSyn software. Unlike Cis, whose activity was lower in the resistant A2780cisR cell line than in the parent A2780 cell line, Andro was found to be three times more active in the A2780cisR cell line as compared to that in A2780 cell line. Synergism was observed when Cis and Andro were administered using the sequences 0/4 h and 4/0 h. The percentage of apoptotic cell death was found to be greater for the 0/4 h combination of Andro and Cis as compared to those values from single-drug treatments. The results may be clinically significant if confirmed in vivo.